The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition inSubjects with Elevated Risk) trial [15] demonstrated that the evolocumab combinedwith intensive statin treatment, as compared with statins alone, significantlydecreased the risk of major ischemic cardiovascular events among patients withstable ASCVD. Here, PCSK9 is linked to atherosclerosis.